The Mary Lake Polan Gynecologic Oncology Research Laboratory
In the United States, ~22,000 women are diagnosed with ovarian cancer every year, and unfortunately, ~14,000 die from this disease. Platinum resistant patients have a lower 5 year progression-free survival rate of 30% which correlates with the development of recurrent disease.
We will evaluate combination drug regimens in women with low response rates to platinum-based chemotherapy treatment. Consequently, we aim to improve the quality of life for advanced stage patients by identifying a novel treatment strategy.
It is crucial for us to understand the mechanism of action for existing drugs and develop a different therapeutic approach for patients with poor prognosis.
Oliver Dorigo, MD, PhD
Dr. Dorigo's clinical responsibilities include the direction of the Gynecologic Oncology Clinical Care Program at Stanford Women’s Cancer Center and the conduction of Gynecologic Oncology clinical trials at Stanford. His research focus as the Director of the Mary Lake Polan Gynecologic Oncology Research Laboratory is the development of novel targeted therapy approaches for ovarian cancer, using cell culture systems, human tissues arrays and mouse models for ovarian cancer.